SeekingAlpha · Aug 17, 2026
MariMed Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-17. The following slide deck was published by MariMed Inc.
MR
OTC · MRMD
MariMed Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.07
Down-$0.01 (-6.62%)
Updated Sep 11, 2026, 6:50 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 29.63M
- P/E ratio
- -1.84
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 65.58K
- Avg. volume
- 1.2M
Price performance
MRMD price history
1M range · 0 trading sessions · Daily adjusted prices
MRMD does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest MRMD news
The latest Smart Investors Daily articles mentioning MRMD.
Stock researchCompany · Overview
MRMD research
Overview
Company profile and research snapshot.
Company profile
MARIMED INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 6, 2023 | Zuanic & Associates | Overweight | — |
| Oct 28, 2022 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 13, 2026
MariMed Inc. (MRMD) Q2 2026 Earnings Call Transcript
MariMed Inc. (MRMD) Q2 2026 Earnings Call August 13, 2026 8:00 AM EDTCompany ParticipantsTimothy RasmussenJon Levine - Co-Founder, CEO, President,...
Yahoo · Aug 12, 2026
MariMed Reports Second Quarter 2026 Earnings
NORWOOD, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2026. Financial Highlights1 The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts): Three months endedJune 30, Six months endedJune 30, 2026 2025 2026 2025 (unaud
Benzinga · Aug 12, 2026
MariMed Q2 Adj. EPS $(0.01), Inline, Sales $41.925M Beat $39.800M Estimate
MariMed (OTC:MRMD) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $41.925 million which beat the analyst consensus estimate of $39.800
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
